1190630-73-9

Upstream product

• 116949-67-8 (2S,3S)-2-azido-1-phenyl-butane-3,4-diol 
• 110-87-2 3,4-dihydro-2H-pyran 
• 136465-96-8 3(S)-azido-4-phenyl-1-(p-toluenesulphonyloxy)-2(S)-butanol 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 1190630-74-0 [(2R,3S)-3-azido-4-phenyl-2-(tetrahydropyran-2-yloxy)butyl]benzylamine 
• 1190630-75-1 (2R,3S)-3-amino-2-tetrahydropyranyloxy-4-phenyl-1-benzylaminobutane 
• 143224-83-3 (2R,3S)-3-Cbz-amino-2-hydroxy-4-phenyl-1-benzylaminobutane 
• 1190630-76-2 [(1S,2R)-1-benzyl-3-benzylamino-2-(tetrahydropyran-2-yloxy)propyl]carbamic acid benzyl ester 
• 1400634-51-6 C₃₄H₄₀N₂O₆ 
• 1190630-70-6 (2R,3S)-3-Cbz-amino-2-hydroxy-4-phenyl-1-(N-benzyl-2-diazo-ethanamido)butane 
• 1190630-69-3 (2R,3S)-3-Cbz-amino-2-hydroxy-4-phenyl-1-(N-benzylacetamido)butane 

Relevant academic research and scientific papers

Nonpeptidic lysosomal modulators derived from Z-Phe-Ala-diazomethylketone for treating protein accumulation diseases

Lysosomes are involved in protein turnover and removing misfolded species, and their enzymes have the potential to offset the defect in proteolytic clearance that contributes to the age-related dementia Alzheimer's disease (AD). The weak cathepsin B and L